GlassScriptPhysician profile
Glenn E Fussell
NPI 1861509184
$2,422.39
in general payments reported to CMS, 2019-2025
24 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $410 · 2021: $722 · 2022: $287 · 2023: $305 · 2024: $287 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $591.88 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $453.27 | 2021-2025 | |
| Lilly USA, LLC | $203.56 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $200.19 | 2019-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $160.30 | 2019-2022 | |
| Esperion Therapeutics, INC. | $151.00 | 2020-2022 | |
| Astellas Pharma US INC | $131.93 | 2021 | |
| Pfizer INC. | $55.70 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $52.79 | 2023-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $40.19 | 2019-2020 | |
| Amgen INC. | $38.72 | 2025 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $37.75 | 2022 | |
| Merck Sharp & Dohme LLC | $37.08 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $35.34 | 2021-2022 | |
| Amarin Pharma, INC. | $33.26 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.99 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.12 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.80 | 2020-2021 | |
| Horizon Therapeutics Plc | $25.74 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $18.65 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $17.88 | 2024 | Farxiga |
| Exact Sciences Corporation | $17.67 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $15.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.40 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Fussell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.